Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06691906 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT06691906 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 40 participants.
The verdict
NCT06691906, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to learn what happens to the amount of enlicitide decanoate in the blood when enlicitide decanoate is given in different formulations.
Interventions
- DRUG Enlicitide decanoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-03-18 |
| Est. Completion | 2024-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06691906
The ClinicalTrials.gov registry entry for NCT06691906 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enlicitide decanoate is the first listed.
NCT06691906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06691906 about?
NCT06691906 is a clinical study titled "A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)". The purpose of this study is to learn what happens to the amount of enlicitide decanoate in the blood when enlicitide decanoate is given in different formulations.
What is the current status of trial NCT06691906?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-03-18. Estimated completion is 2024-05-01.
What interventions are being tested in trial NCT06691906?
The interventions under investigation include: Enlicitide decanoate (DRUG).
Who is sponsoring clinical trial NCT06691906?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.